Guanabenz is an alpha-2 adrenergic agonist used to treat hypertension. A medication used to treat high blood pressure.
- Mechanism
- Curator reviewed
Guanabenz's antihypertensive effect is thought to be due to central alpha-adrenergic stimulation, which results in a decreased sympathetic outflow to the heart, kidneys, and peripheral vasculature in addition to a decreased systolic and diastolic blood pressure and a slight slowing of pulse rate. Chronic administration of guanabenz also causes a decrease in peripheral vascular resistance.
- Primary indication
- For management of High blood pressureCurator reviewed
- Formula / weight
- C8H8Cl2N4 · 231.08 g/mol (avg)
- First approval
- United States, 1995
- Also known as
- [(2,6-Dichlorobenzylidene)amino]guanidine · 2-((2,6-DICHLOROPHENYL)METHYLENE)HYDRAZINECARBOXIMIDAMIDE · HYDRAZINECARBOXIMIDAMIDE, 2-((2,6-DICHLOROPHENYL)METHYLENE)- · N-(2,6-DICHLOROBENZYLIDENE)-N'-AMIDINOHYDRAZINE
- Code names
- BR 750 · FLA 137 · GBZ · NSC-68982 · SD 15468 · WY-8678
Resolves to
Clinical / RWD
Structure
InChIKey
WDZVGELJXXEGPV-YIXHJXPBSA-NSMILESNC(=N)N\N=C\C1=C(Cl)C=CC=C1ClTargets
What you can answer from here — as of September 23, 2026
3Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Guanabenz, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account